All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
California Vol.26 (corporations: Gilead Sciences)
上記リンク内に無い本日までのツイート
Read an open letter from our Chief Medical Officer about today's @US_FDA approval of our antiviral treatment for COVID-19. https://t.co/JAyK3zJGD7
— Gilead Sciences (@GileadSciences) October 22, 2020
The @US_FDA today approved our antiviral to treat patients with COVID-19 requiring hospitalization. Read more: https://t.co/Z5lO227KVU. pic.twitter.com/NqebDeoWBv
— Gilead Sciences (@GileadSciences) October 22, 2020
We released the following statement today related to the WHO SOLIDARITY trial for the treatment of COVID-19 https://t.co/YzAy1EgnVV.
— Gilead Sciences (@GileadSciences) October 16, 2020
.@US_FDA gave its final nod to @GileadSciences #Remdesivir for treating hospitalised Covid-19 patients. @viswanath_pilla reports. #COVI19 #CoronavirusIndia #COVIDIndia https://t.co/zX7bUsJSES
— moneycontrol (@moneycontrolcom) October 23, 2020
5 Penny Stocks To Watch After Gilead Sciences' Big Remdesivir News https://t.co/fze9H7hBwI
— EIN Presswire: Lung Cancer Newswire (@EINLungCancer) October 23, 2020
NEW: Gilead Sciences has announced that the FDA has approved remdesivir for treating COVID-19. The antiviral drug becomes the first drug to receive full approval from the FDA for treatment against the coronavirus, according to the pharmaceutical company. https://t.co/FGiIkZOtPk pic.twitter.com/m9XIdaVMsE
— WebMD (@WebMD) October 22, 2020
NEW: FDA approves remdesivir to treat Covid-19, making it the first and only drug so far to have received federal approval for the coronavirus. https://t.co/NddlmHEfOo
— MSNBC (@MSNBC) October 22, 2020
BREAKING: FDA approves first COVID-19 drug, remdesivir https://t.co/C5outLVVNF
— CBS News (@CBSNews) October 22, 2020
BREAKING: FDA approves Gilead's remdesivir as coronavirus treatment https://t.co/ryNKPD9vhB
— CNBC Now (@CNBCnow) October 22, 2020
Remdesivir receives FDA approval to treat hospitalized COVID patients @drsanjaygupta reports pic.twitter.com/OxqCn3RKdM
— The Lead CNN (@TheLeadCNN) October 22, 2020
JUST IN: The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, says https://t.co/8pg6cHwRoB
— CNN (@CNN) October 22, 2020
Remdesivir is the first and only fully FDA-approved drug in the U.S. for treating the coronavirus. https://t.co/dtYQNytzch
— Axios (@axios) October 22, 2020
The news has barely mentioned it, but Big Pharma company Gilead is charging $3,000 for a coronavirus drug that costs them less than $10 to produce.
Once again, they're set to profit on the people's dime.
— Robert Reich (@RBReich) October 21, 2020
NEW: Gilead Sciences just received FDA approval for remdesivir. This is the inside story of how the company prepared for the pandemic https://t.co/VPXM3GjcbM pic.twitter.com/M4vwD8lNcD
— Businessweek (@BW) October 22, 2020
FDA just approved the first COVID-19 drug AND it's from @OceansideBiz-based@GileadSciences
Details here: https://t.co/pX2vmc6ZiT?— Innovate78 (@Innovate_78) October 22, 2020
@CityofOceanside's @GileadSciences #COVID19 drug now @US_FDA approved! https://t.co/jYYZjfIVNC
— San Diego North EDC (@SDNorthEDC) October 22, 2020
https://twitter.com/SDRegionalEDC/status/1319400169650073600
Morning Bell: #ASX200 to open flat with all eyes on the #USPresidentialDebate2020 at 11am AEDT. U.S. FDA approves @GileadSciences' #COVID19 treatment. Trading ideas: $ALL, $LBY, $AIS, $NGI, $MYQ & $TSO. #ausbiz #belldirect #tradingideas https://t.co/xblREmVKkU
— Bell Direct (@belldirect) October 22, 2020
The @US_FDA has approved the first drug treatment for #COVID19 in the US, and antiviral by @GileadSciences #remdesivir https://t.co/lrYd1NB3gq pic.twitter.com/byXuRUa4Pe
— Pharmacy Times (@Pharmacy_Times) October 22, 2020
.@US_FDA approves @GileadSciences's remdesivir as the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.https://t.co/QbzL80S6oN #optometry #COVID19 #remdesivir pic.twitter.com/rcDZewIRgk
— Optometry Times (@OptometryTimes) October 22, 2020
#BREAKING Remdesivir becomes first FDA fully-approved coronavirus treatment https://t.co/VAwD4PgPZI
— KTNV 13 Action News (@KTNV) October 22, 2020
Thank you to @GileadSciences for choosing PPD to help support the clinical development program of your important new COVID-19 treatment. https://t.co/xuzXL3Cqpy#ppd #covid19 #coronavirus #pandemic #followthescience #wereinthistogether #wegotthis #relentless #collaborate pic.twitter.com/81yZNEFNcC
— PPD (@PPDCRO) October 22, 2020
ICYMI: The FDA approved Remdesivir for the treatment of coronavirus infection, says the drug's maker, Gilead Sciences. https://t.co/TMDKdaRrw4
— CBS46 (@cbs46) October 23, 2020
JUST IN: The FDA has approved Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus. Remdesivir is now the first and only fully approved treatment in the U.S. https://t.co/tdD2A5IkDB
— NBC Bay Area (@nbcbayarea) October 22, 2020
The FDA has approved #remdesivir for the treatment of #COVID19, Bay Area-based Gilead Sciences, said Thursday. https://t.co/Wix6PGn7vw
— ABC7 News (@abc7newsbayarea) October 22, 2020
JUST IN: The FDA has officially approved remdesivir as a treatment for coronavirus, drug manufacturer Gilead Sciences announced.https://t.co/MZtO88r2eS
— New York Daily News (@NYDailyNews) October 22, 2020
The @NIH has paused a phase 3 study on @LillyPad’s #Covid19antibody treatment on a potential safety concern. The #NIH-sponsored study is testing bamlanivimab (LYCoV555) in combination with @GileadSciences’s #Remdesivir in hospitalized patients. https://t.co/bip662pVW9
— CHEManager International (@CHEManager_EU) October 22, 2020
.@GileadSciences’ Remdesivir Flunks WHO Trial, Gains “Prequalified” Status. Learn more:https://t.co/4LWvAJnhMb pic.twitter.com/xDLUSFqesK
— Genetic Engineering & Biotechnology News (@GENbio) October 19, 2020
News for #pharma #marketers: Mon, Oct 19
-More than 25% of state legislators accepted pharma campaign contributions since 2019
– @Pfizer won’t seek emergency authorization of vaccine until late Nov.
– @GileadSciences Remdesivir failed to prevent deathshttps://t.co/IAaXOVHudQ— MM+M Magazine (@MMMnews) October 19, 2020
ICYMI: Future of Gilead's #remdesivir for COVID-19 in doubt after WHO reveals trial data @GileadSciences #covid19 #WHOhttps://t.co/4j6ij1AD6j pic.twitter.com/Ex8jNDr631
— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020
WHO trial shows @GileadSciences Veklury (remdesivir) has no effect on mortality and hospital stay in COVID-19 – data is inconsistent with US studies used to support Emergency Use Authorization https://t.co/4LZOdhzd8J
— pharmaphorum (@pharmaphorum) October 16, 2020
Results from the WHO’s highly anticipated Solidarity trial found that none of the treatments ‘substantially affected mortality’ or reduced the need to ventilate patients, according to a copy of the study seen by the FT https://t.co/yuKtO8sojn pic.twitter.com/LegWL7ryGI
— Financial Times (@FinancialTimes) October 15, 2020
The US Food and Drug Administration has approved the first drug to treat COVID-19 – Remdesivir. Gilead Sciences Inc says the antiviral medicine, given through an IV for patients needing hospitalisation, cut the time for recovery by five days — from 15 days to 10 on average. pic.twitter.com/gJ5TfeROoY
— Jamaica Gleaner (@JamaicaGleaner) October 22, 2020
@US_FDA approves Gilead’s Remdesivir to treat #COVID19, even though @WHO's study found drug not effective @DrTedros @realDonaldTrump @JoeBiden @KamalaHarris @Mike_Pence @CDCgov @AfricaCDC @NIH @GileadSciences #Election2020 https://t.co/AxP8HjKLz0 via @todaynewsafrica
— TODAY NEWS AFRICA (@todaynewsafrica) October 22, 2020
Investors betting on big profits from #COVID19 treatments may get an unwelcome surprise when @GileadSciences reports quarterly results this month as remdesivir, the first important coronavirus treatment, has not been used as much as first expected. https://t.co/R9ywTIGL7T pic.twitter.com/aiINMXzsuE
— Arab News Japan (@ArabNewsjp) October 17, 2020
FDA approves Gilead Sciences' antiviral drug for treating patients hospitalized with COVID-19. https://t.co/RMKapXSqij
— Arutz Sheva (@ArutzSheva_En) October 22, 2020
Remdesivir has very little effect on Covid-19 mortality, WHO finds https://t.co/ehhGOoTtVV
— The Guardian (@guardian) October 16, 2020
So, has #remdesivir shown a survival benefit? I remember @icer_review suggested that without a survival benefit the price should be about $310. The drug costs $3,120 now. Am I missing something or are we getting price-gouged (again) by @GileadSciences?
— Gregg Gonsalves (@gregggonsalves) October 16, 2020
Gilead received the Solidarity manuscript ruling out a big impact from remdesivir on #covid19 mortality on 28 September according to @WHO.
On 8 October, before the results became public, Gilead signed a billion dollar deal with the EU Commission for remdesivir.
I have questions
— Kai Kupferschmidt (@kakape) October 16, 2020
As #IDWeek2020 spotlights the impact of the #COVID19 pandemic on fighting #HIV, learn how our CARES Grantee Fund is supporting community organizations during this difficult time.
— Gilead Sciences (@GileadSciences) October 22, 2020
The data presented at #IDWeek2020 highlight our commitment and efforts to assess and address unmet needs in #HIV treatment. Learn more here: https://t.co/7p4UfPVE9v pic.twitter.com/OCWbVbaH99
— Gilead Sciences (@GileadSciences) October 21, 2020
#HIV is not a crime. Those living with and at risk for HIV are often held back by laws that discourage people from getting tested or treated.
Learn more from Health Not Prisons Collective, who joined the panel discussion at #2020USCHA.
— Gilead Sciences (@GileadSciences) October 20, 2020
#HealthDisparities can prevent access to HIV care and treatment in Black communities. Progress in ending the #HIV epidemic means not leaving anyone behind.
Join our conversation at #2020USCHA around ending health disparities in HIV.
— Gilead Sciences (@GileadSciences) October 19, 2020
“Peer-to-peer programs work because there’s nothing unreal about it. It’s raw and it’s truth.” Tune in to the #Hepcast, made in collaboration with @Hep_Alliance, to hear how Tony McClure of @HepatitisCTrust helps engage people living with #hepatitisC.
— Gilead Sciences (@GileadSciences) October 16, 2020
This National Latinx AIDS Awareness Day, meet Bamby Salcedo, founder of @TransLatina_C and an advocate for #HIV awareness and prevention. #NLAAD
— Gilead Sciences (@GileadSciences) October 15, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Japan's health ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc's antiviral drug remdesivir. #Japan #Coronavirus #CoronavirusVaccine https://t.co/VM96hBlMJo
— IndiaToday (@IndiaToday) July 22, 2020
Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease. https://t.co/oZggDtgDyq
— GMA News (@gmanews) May 7, 2020
Japan approves Gilead Sciences' remdesivir as COVID-19 drug https://t.co/EP6Brqywfb pic.twitter.com/7UeR0czgl2
— Reuters (@Reuters) May 7, 2020
Japan approves Gilead Sciences' #Remdesivir as #COVID19 drug. $GILD https://t.co/lJeYKLbitp
— Bio Stocks™ (@BioStocks) May 7, 2020
"Japan on Saturday began to fast-track the approval of remdesivir, Gilead Sciences' antiviral drug intended to treat coronavirus patients… It has also asked the U.S. to ensure Japan receives adequate supplies of the drug."https://t.co/bqxF9ODV9I
— DUTERTENOMICS (@Dutertenomics) May 2, 2020
https://twitter.com/FinancialTimes/status/1258289223121043456
#SunStarWorldNews
TOKYO — Japan has approved Gilead Sciences’ antiviral drug remdesivir for coronavirus treatment in a fast-track review just four days after the US company submitted an application.https://t.co/YoDxFOMWR4— Sun Star Davao (@SunStarDavao) May 8, 2020
U.S. drugmaker Gilead has an experimental antiviral drug that may work against the coronavirus. It's unapproved for use in humans, but hey it appears to have worked on the first U.S. infection case in Washington state.@joewalkerWSJ https://t.co/zjXUG7rAJY
— Jonathan Cheng (@JChengWSJ) February 1, 2020
Gilead Sciences and Japan Tobacco signed a letter of intent to dissolve their licensing partnership, the cigarette company said Monday, as the U.S. drugmaker prepares to market a new HIV treatment in Japan on its own. https://t.co/WhK2ynVZpX MT @NAR pic.twitter.com/WnfoUz4J9d
— HIV Insight (@HIV_Insight) September 1, 2018
Gilead and Eisai announce co-promotion agreement for investigational rheumatoid arthritis treatment in Japan: https://t.co/ia8aFkxONY.
— Gilead Sciences (@GileadSciences) December 24, 2019
SFBN Feed: Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis: FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today … #BayArea #Biotech https://t.co/y7JaL4nXwM
— San Francisco Biotechnology Network (@sfbionetwork) September 25, 2020
Gilead Sciences and Eisai Agreed on Distribution and Co-Promotion of Filgotinib – https://t.co/xHtO20gxBa pic.twitter.com/8XM09CgNkO
— GMPnews.Net (@GMPnewsNet) December 30, 2019
Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan @GileadSciences @EisaiUS
https://t.co/92Bp0R5v30— PharmaShots – Incisive news in 3 shots (@Pharmashot) December 26, 2019
